Paul Mudd

Paul Mudd, Chief Development Officer at Priovant, has over 20 years of experience in the pharmaceutical industry. Paul began their career at GlaxoSmithKline (GSK), where they spent 3 years as a Senior Director in Clinical Pharmacology. Paul then transitioned to Urovant Sciences, Inc., where they served as VP of Clinical Development for 2 years before being promoted to SVP of Clinical Development and Health Outcomes. In this role, they oversaw all aspects of clinical development, from early phase through registration and commercialization. Paul also led the team responsible for developing and executing the health outcomes strategy for Urovant's products. In July 2018, they rejoined GSK as a Chief Development Officer in Residence at Roivant Sciences. In this role, they provided strategic and operational oversight for Roivant's clinical development activities. Paul left Roivant in December 2021 to join Priovant as Chief Development Officer.

Paul Mudd has a MBA from UNC Kenan-Flagler Business School, a Fellowship from the University of North Carolina at Chapel Hill in Clinical PK/PD, and a Pharm D from the University at Buffalo in chemistry and Pharmacy.